Quest Diagnostics (DGX), Why Is It Getting Attention Today?

What Apple's Health Integration Signals For Quest Diagnostics

Quest Diagnostics (DGX) is teaming up with Apple Health to sell a $119 lab panel covering more than 50 biomarkers directly inside the app, with results flowing back into iPhone and iPad.

The package focuses on cardiometabolic markers and organ function, paired with biometric readings like blood pressure and waist measurements, and is designed to make preventive testing easier for users who want more regular health tracking.

Quest Diagnostics shares have gained momentum over 2026, with a 90 day share price return of 18.33% and a year to date share price return of 36.88%, while the 3 year total shareholder return of 100.57% points to strong longer term compounding.

The Apple Health integration builds on this upward trend and follows the recent Renalytix agreement that plugs kidneyintelX.dkd into Quest Diagnostics connectivity. Traders appear to be reacting to a story that now blends direct to consumer testing with specialized clinical partnerships.

Capitalize on Quest Diagnostics' push into app based diagnostics by scanning a curated group of healthcare stocks building similar consumer health and digital testing exposure through the 40 healthcare AI stocks.

Bulls see Quest Diagnostics turning consumer demand for app based health checks into durable earnings power. Bears see a one off story already reflected in the share price. Which view matches the current valuation setup?

Most Popular Quest Diagnostics Narrative: 3.2% Undervalued

Quest Diagnostics last closed at $237.89, while the most followed narrative pegs fair value around $245.87. This points to a small valuation gap that hinges on how convincingly new testing and data initiatives translate into cash flows under a 7.24% discount rate.

The rising importance of health data analytics and Quest's role as a "lab engine" for consumer wellness brands positions the company to benefit from new revenue streams and further monetization opportunities as healthcare becomes more data-driven, supporting long-term earnings power.

See why 19 investors see Quest Diagnostics as 3% undervalued.

Result: Fair Value of $245.87 (UNDERVALUED)

Still, reimbursement changes, such as potential PAMA cuts and a higher mix of government backed payers, could pressure Quest Diagnostics' pricing power and future margin assumptions.

Find out about the key risks to this Quest Diagnostics narrative.

Next Steps

Mixed signals on Quest Diagnostics so far. Act quickly, review both the upside and concerns, then weigh the 3 key rewards and 1 important warning sign.

Looking for more Quest Diagnostics investment ideas?

Do not stop with Quest Diagnostics. Broaden your watchlist with fresh opportunities now, or you risk missing stocks that better match your goals and risk comfort.

• Target potential value upside by scanning a tight group of companies that look mispriced on quality and fundamentals through 35 high quality undervalued stocks.
• Prioritize capital preservation first and hunt for steadier performers by reviewing 11 resilient stocks with low risk scores.
• Spot lesser known opportunities with strong foundations before they hit the mainstream by running 15 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com